Venture Investment May Dip, But Capital Remains Plentiful
Headwinds may be growing for private company investment, but investors at the BIO CEO & Investor conference remain optimistic about the general outlook.
You may also be interested in...
Global Uncertainty Is Impacting Deal-Making, Investment Decisions
Deloitte chief global economist Ira Kalish said in a Biocom webinar that the war in Ukraine increased existing macroeconomic uncertainty, which is keeping businesses and investors from deploying capital.
Finance Watch: Atlas Raises $450m Venture Fund For Biotech Breakthroughs
Both Atlas and Foresite Capital announced new funds focused on start-ups. Also, Flagship launched Vesalius with $75m in initial funding, Innoviva sold $225m in notes, Hookipa priced a $75m follow-on offering and job cuts were revealed by Epizyme, Flexion, Deciphera and Gemini.
Foresite Sees Plenty Of Investor Interest In Biopharma As It Raises $173m Fund
With its new fund for companies emerging from Foresite Labs, Foresite Capital has raised more than $1bn in new venture capital during the past year to back life science and health care innovation.